
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Results from a small pilot study suggest that topical tacrolimus ointment 0.1 percent (Protopic) may be a promising new treatment for seborrheic dermatitis, researchers from Emory University School of Medicine, Atlanta, reported.